NTLA Q2 2018 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+29.7% YoY

Gross Profit

-$16M-205.7% margin

Operating Income

-$24M-307.3% margin

Net Income

-$22M-289.4% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$340M

Total Liabilities

$60M

Stockholders' Equity

$279M

Cash & Equivalents

$306M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+29.7%
Gross Profit	-$16M	-$10M	-63.7%
Operating Income	-$24M	-$16M	-47.3%
Net Income	-$22M	-$16M	-42.5%